Agilent | Trusted AnswersAgilent | Trusted Answers

November 16-18, 2023

Discover Agilent Avida:

Multiomic Enrichment Solution

Welcome to the Agilent family, Avida Biomed!

Press Release
Agilent at AMPExclusive ContentEarly AccessGet in Touch

AMP Innovation Spotlight 

Thursday, November 16, 2023

12:00p.m. - 12:30p.m. 


John Palma, Ph.D, VP, Global Head of Medical Affairs at Agilent 

Bellal Moghis, MS, MBA, Director of Product Marketing & Strategy for Diagnostics and Genomics Group at Agilent

Solving Challenges In Multiomic Testing Using The New Agilent Avida Dual-Target Enrichment Solution

DNA methylation alterations are emerging cancer biomarkers that have the potential to improve disease management and aid in early detection. Promising multiomic solutions are being developed to overcome technical challenges associated with testing for multiple biomarkers from limited sample. 

Join Agilent to learn more about: 

  • The potential impact of emerging biomarkers in cancer screening, monitoring, and treatment 
  • A novel solution for targeted cfDNA mutation and methylation sequencing analysis with high analytical sensitivity and specificity, without sample splitting. 
  • A powerful approach that concurrently supports tumor-informed mutation and tumor-independent methylation strategies, identifying both cancer presence and personalized treatment options in one assay. 

Access Exclusive Avida Multiomic Data

Send me Exclusive Avida Content

Early Access: Get your hands on the future today!

Reserve Your Spot Now

Explore the Entire Agilent NGS Workflow

Interactive Lab

For Research Use Only. Not for use in diagnostic procedures.

PR7001-1316

I would like more information

Fill out this form to get technical information and early access to Agilent’s newest multiomics solution- Avida! Coming soon.

Get in Touch

* This field is required








For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policy